地球，人間煉獄 XCIX(99th、九十九) ： Blood Clots: The Risks, if Any, Are Very Low. Denmark. Japan is rolling out COVID-19 vaccinations. Thailand reports. 多國疫苗數據分析；美國建議暫停接種強生新冠疫苗以調查罕見血栓病例Johnson & Johnson:New Concerns

Japan is rolling out COVID-19 vaccinations for its 36 million elderly people – but demand far outstrips current supply.

****

BREAKING: Denmark decides not to resume use of AstraZeneca's Covid vaccine following reports of rare blood clots.

J&J Vaccine and Blood Clots: The Risks, if Any, Are Very Low

The F.D.A. is investigating the extremely rare blood clots, and experts say the benefits of the vaccine still far outweigh the

****
More than a quarter of the new COVID-19 cases reported today were in Bangkok.
CHANNELNEWSASIA.COM
Thailand reports daily record of more than 1,300 new COVID-19 cases

-----

Pause on Johnson & Johnson’s Vaccine Fuels New Concerns

• Some health officials fear a focus on rare potential side effects may increase hesitancy — and coronavirus exposure.

美國建議暫停接種強生新冠疫苗以調查罕見血栓病例

美國衛生當局建議暫停使用強生公司的新冠疫苗，以調查罕見但嚴重的血栓病例。強生公司並表示，推遲原定本月晚些時候在歐洲推出其新冠疫苗的計劃。

Johnson & Johnson Statement on COVID-19 Vaccine

NEW BRUNSWICK, N.J., April 13, 2021– The safety and well-being of the people who use our products is our number one priority. We are aware of an extremely rare disorder involving people with blood clots in combination with low platelets in a small number of individuals who have received our COVID-19 vaccine. The United States Centers for Disease Control (CDC) and Food and Drug Administration (FDA) are reviewing data involving six reported U.S. cases out of more than 6.8 million doses administered. Out of an abundance of caution, the CDC and FDA have recommended a pause in the use of our vaccine.

In addition, we have been reviewing these cases with European health authorities. We have made the decision to proactively delay the rollout of our vaccine in Europe.

We have been working closely with medical experts and health authorities, and we strongly support the open communication of this information to healthcare professionals and the public.

The CDC and FDA have made information available about proper recognition and management due to the unique treatment required with this type of blood clot. The health authorities advise that people who have received our COVID-19 vaccine and develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider.

For more information on the Janssen COVID-19 vaccine, click here.

 ----

D100 Fans Club

【互動專頁】多國疫苗數據分析

英美新增確診持續下降 　智利接種科興確診率不跌反升

【報道全文、更多圖表：https://bit.ly/3dRdqub 】

全球多月來開始接種不同的武漢肺炎 (COVID-19) 疫苗，部份國家在廣泛接種疫苗後，確診率明顯下降，但同時亦有多國確診率不跌反升。

香港現有兩款疫苗供接種 — 國產的科興疫苗及德國研發的 BioNTech，兩者也在不同國家接種。約一半接種 BioNTech 的美國，疫情明顯好轉，但主要接種科興的智利，新增確診有上升趨勢。不過疫情反反覆覆，除了與接種不同疫苗有關，亦會被多個其他因素影響，例如當地有否放寬限制措施，接種疫苗的人口比例，以及有否變種病毒株肆虐等等。

智利是全球其中一個接種率最高的國家，現時全國已有 34% 人接種疫苗，而當地九成接種的都是中國科興疫苗。當地自一月中開始接種後，新增確診人數有上升趨勢，現時每週每百萬人有 2,427 人確診，比 3 月初多逾 1,000 人。主因相信與該國在未有足夠人口接種疫苗達到「群體免疫」時，已重開賭場、戲院與健身室等場所，令國民錯誤以為疫情最壞情況而過，結果疫情反彈，並須重新封城…

資料/圖片來源： Stand News 立場新聞

前往新冠病毒資訊中心查看疫苗相關資源。

取得疫苗相關資訊

88